BETAMETHASONE SUMMARY
Betamethasone Dipropionate Cream, USP 0.05% (Augmented)*
Betamethasone dipropionate cream (augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17,21-dipropionate ester of betamethasone.
Betamethasone dipropionate cream (augmented) is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.
|
NEWS HIGHLIGHTSMedia Articles Related to Betamethasone (Betamethasone Topical)
clotrimazole and betamethasone, Lotrisone
Source: MedicineNet Ringworm Specialty [2009.01.09]
Title: clotrimazole and betamethasone, Lotrisone
Category: Medications
Created: 12/31/1997
Last Editorial Review: 1/9/2009
Published Studies Related to Betamethasone (Betamethasone Topical)
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. [2009.09]
BACKGROUND: Genetic defects leading to skin barrier dysfunction were recognized as risk factors for atopic dermatitis (AD). It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. OBJECTIVES: We investigated the effect of 2 common treatments, a calcineurin inhibitor and a corticosteroid, on the skin barrier... CONCLUSION: The present study demonstrates that both betamethasone and pimecrolimus improve clinical and biophysical parameters and epidermal differentiation. Because pimecrolimus improved the epidermal barrier and did not cause atrophy, it might be more suitable for long-term treatment of AD.
Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. [2009.08]
BACKGROUND: Psoriasis vulgaris of the scalp has a significant psychosocial impact on individuals affecting their quality of life (QoL). A combination of calcipotriol and betamethasone dipropionate in a formulation suitable for treatment of scalp psoriasis has been developed. OBJECTIVE: To assess the impact of treatment with either calcipotriol plus betamethasone dipropionate scalp formulation or calcipotriol scalp solution on QoL in patients with scalp psoriasis (both within and between treatment groups)... CONCLUSION: The two-compound scalp formulation was superior to calcipotriol scalp solution in improving QoL in patients with scalp psoriasis.
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. [2009.07]
BACKGROUND: Current topical therapies for scalp psoriasis are difficult or unpleasant to apply, resulting in decreased adherence and efficacy. OBJECTIVES: To compare the efficacy and safety of once-daily treatment with a combination of calcipotriol 50 microg g(-1) plus betamethasone 0.5 mg g(-1) (as dipropionate) (Xamiol; LEO Pharma A/S, Ballerup, Denmark) and twice-daily calcipotriol 50 microg mL(-1) scalp solution in patients with scalp psoriasis... CONCLUSIONS: A once-daily combination of calcipotriol plus betamethasone dipropionate was significantly more effective and better tolerated than twice-daily calcipotriol scalp solution in the treatment of scalp psoriasis.
The effects of betamethasone treatment on clinical and laboratory features of pregnant women with HELLP syndrome. [2009.07]
AIM: The present study aims to investigate the effects of betamethasone treatment on clinical outcome and laboratory data of pregnant women diagnosed with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome... CONCLUSIONS: The betamethasone treatment has ended up with insignificant alterations in clinical outcomes and laboratory data of women with HELLP syndrome except beneficial effects on metabolic complications and need for platelet transfusion. Further investigation is required to assess the efficiency of betamethasone in management of HELLP syndrome.
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. [2009.05]
BACKGROUND: Genetic defects leading to skin barrier dysfunction were recognized as risk factors for atopic dermatitis (AD). It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. OBJECTIVES: We investigated the effect of 2 common treatments, a calcineurin inhibitor and a corticosteroid, on the skin barrier... CONCLUSION: The present study demonstrates that both betamethasone and pimecrolimus improve clinical and biophysical parameters and epidermal differentiation. Because pimecrolimus improved the epidermal barrier and did not cause atrophy, it might be more suitable for long-term treatment of AD.
Clinical Trials Related to Betamethasone (Betamethasone Topical)
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel
with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this
time all patients will receive the gel containing both calcipotriene and betamethasone for 44
weeks. In addition, patients will receive an ointment containing both calcipotriene plus
betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.
The objective is to study the short-term efficacy of the gel, and the short and long-term
safety of the gel and the ointment.
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus [Completed]
Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but
corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore,
an alternative medication with the same efficacy, but without the side-effects is sought
after.
Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its
efficacy in treating discoid lupus erythematosus has not been studied extensively yet.
However studies performed till now show promising results. Long-term topical use of this
medication has not shown any serious side-effects in other skin diseases.
In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic
choice, betamethasone valerate 0. 1% cream, to see if pimecrolimus can be used as an
alternative medication in treating discoid lupus erythematosus.
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis [Completed]
The purpose of the study is to evaluate whether once daily topical treatment for up to 8
weeks of calcipotriol 50 mcg/g plus betamethasone 0. 5 mg/g (as dipropionate) gel is safe and
more effective than betamethasone 0. 5 mg/g (as dipropionate) in the gel vehicle and
calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis.
The primary response criterion is the number of patients with absence of disease and very
mild disease after 8 weeks of treatment.
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris [Completed]
The objective of the study is to compare the use of calcipotriol plus betamethasone
dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel
vehicle and the gel vehicle alone when used in patients with psoriasis vulgaris on the trunk
and/or limbs. Patients will be treated once daily for up to 8 weeks.
The primary response criterion is the number of patients with controlled disease at week 8.
Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis [Completed]
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of
calcipotriol 50 mcg/g plus betamethasone 0. 5 mg/g (as dipropionate) gel is safe and more
effective than betamethasone 0. 5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50
mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis.
The primary outcome is the proportion of patients with absence of disease or very mild
disease after 8 weeks of treatment.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 2 ratings/reviews, Betamethasone has an overall score of 4. The effectiveness score is 5 and the side effect score is 5. The scores are on ten point scale: 10 - best, 1 - worst.
| | Betamethasone review by 45 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Moderate Side Effects | | |
Treatment Info |
| Condition / reason: | | eczema |
| Dosage & duration: | | once daily (dosage frequency: once daily for one or two days) for the period of 40 years |
| Other conditions: | | allergies to dust, mold, pollen, seafood, asthma |
| Other drugs taken: | | hydrocortisone, inhalers (corticosteroid) for asthma | | |
Reported Results |
| Benefits: | | This cream preparation worked well, but over the years I ntoiced it was less effective. I have used it very sparingly but I no linger use it on my hands becaue it causes seems to worsen the condition of the skin to split the skin in inflamed areas after application. I use weaker hydrocortisone cream on my hands as a last resort. Luckily that cream is just stron enough to offer some relief. |
| Side effects: | | Over time (many years) I ntoiced reduced effectiveness and splitting of the skin in inflamed areas (on hands), despite using this product very sparingly. |
| Comments: | | I use this cream as little as possible - only when I have a serious flare-up of the eczema. When I do use the cream I apply a reasonable amount to the skin - just enough to makae sure some cream comes in contact with all of the inflamed area. I use the cream once or twice a day during the flare up. Once I notice the inflammation is going down I stop using it- and teh skin finishes healing up on its own without further nedication. I rinse the cream off my hands after applying becaue it is not helpful to treat eczema on my hands anymore. |
|
| | Betamethasone review by 71 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Ineffective |
| Side effects: | | Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | Trochanteric Bursitis |
| Dosage & duration: | | 5 mg/amp + 2 mg/amp taken injection for the period of two injectios |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | After the administration of the first injection the pain decreased, however after a period of two weeks it returned. A second injection was administered. There was no improvement and undesirable side effects, as described below, appeared. |
| Side effects: | | Two days after the 2nd injection the body weight started to increase. In the forth day it was 1.5 kg heigher. In the following four days it returned to almost normal. During this period I felt tired and dizzy and fainted at one occasion. The blood test indicated that the concentrations of potassium and sodium were outside the normal limits (Potassium too high, 5.3 mmol/L and sodium too low, 134 mmol/L), in a dangerous range. Similarly to the pH, the safe range for these two ions is narrow. Four days later the potassium was OK, 5.1 mmol/L albeit high, but the sodium, remained unchanged. In additional three days, the sodium was OK,136 mmol/L ,albeit low. I continued to feel tired for the next two weeks |
| Comments: | | Two injections were administered in a period of two weeks |
|
|
|
Page last updated: 2009-10-20
|
